Translational strategies for cancer prevention in liver

Nature Reviews Cancer

Volumn 3, Issue 5, 2003, Pages 321-329

  Kensler, Thomas W ^a   Qian, Geng Sun ^b   Chen, Jian Guo ^c   Groopman, John D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b SHANGHAI CANCER INSTITUTE   (China)

^c QIDONG LIVER CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ANDROGEN; MYCOTOXIN; ORAL CONTRACEPTIVE AGENT;

ALCOHOL CONSUMPTION; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; DEVELOPING COUNTRY; DIETARY INTAKE; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; VACCINATION; WATER POLLUTION; LIVER TUMOR;

AFLATOXINS; CHEMOPREVENTION; HUMANS; LIVER NEOPLASMS;

EID: 0038049147     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1076     Document Type: Review

References (91)

1. Parkin, D. M., Pisani, P. & Feday, J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841 (1999).
2. Li, L. & Rao, K. (eds) Cancer Incidence and Mortality in Cities and Counties of P. R. China 1988-1992 (China Medical Science and Technology Press, 2001).
3. Jemel, A. et al. Cancer statistics 2003. CA Cancer J. Clin. 53, 5-26 (2003).
4. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: a Global Perspective (American Institute for Cancer Research, Washington DC, 1997).
5. Chen, J.-G. et al. Population-based cancer survival in Qidong, People's Republic of China. IARC Sci. Publ. 145, 27-35 (1998).
6. Mencan, I. et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 15, 1356-1361 (2000).
7. Ogunbiyi, J. O. Hepatocellular carcinoma in the developing world. Semin. Oncol. 28, 179-187 (2001).
8. Etzel, R. A. Mycotoxins. JAMA 287, 425-427 (2002).
9. Aflatoxins. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans 82, 171-300 (2002).
10. Hahn, W. C. & Weinberg, R. A Modeling the molecular circuitry of cancer. Nature Rev. Cancer 2, 331-341 (2002)
11. Vogelstein, B. & Kinzler, K. W. (eds) The Genetic Basis of Human Cancer 2nd edn (McGraw-Hill, New York, 2002).
12. Herman, J. G. Hypermethylation pathways to colorectal cancer. Implications for prevention and detection. Gastroenterol. Clin. North Am. 31, 945-958 (2002).
13. Thorgeirsson, A. & Grisham, J. W. Molecular pathogenesis of human hepatocellular carcinoma. Nature Genet. 31, 339-346 (2002).
14. Seeger, C. & Mason, W. S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64, 51-68 (2000).
15. Hoofnagle, J. H. & Schafer, D. F. Serologic markers of hepatitis B virus infection. Semin. Liver Dis. 6, 1-10 (1986).
16. Weiland, O. & Schvarcz, R. Hepatitis C: virology, epidemiology clinical course, and treatment. Scand. J. Gastroenterol. 27, 337-342 (1992).
17. Plaa, G. L. & Hewitt, W. R. in Principles and Methods of Toxicology 2nd edn (ed. Hayes, A. W.) 599-628 (Raven Press, New York, 1989).
18. Colombo, M. Hepatitis C virus and hepatocellular carcinoma. Baillière's Clin. Gastroenterol. 13, 519-528 (1999).
19. El-Serag, H. B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36, S75-S83 (2002).
20. Zein, C. O. & Zein, N. N. Advances in therapy for hepatitis C infection. Microbes Infect. 4, 1237-1246 (2002).
21. 1 in vitro. Proc. Natl Acad. Sci. USA 74, 1870-1874 (1977).
22. 1 in vivo in rats. Carcinogenesis 8, 819-824 (1987).
23. 1-treated rats. Cancer Res. 41, 650-654 (1981).
24. Ross, R. K. et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339, 943-946 (1992). This study was the first to show the synergistic interaction between aflatoxin exposure and infection with hepatitis B virus (HBV) in the aetiology of hepatocellular carcinoma (HCC).
25. Qian, G.-S. et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 3, 3-10 (1994).
26. Sun, Z.-T. et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen cancers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30, 379-383 (1999).
27. Wang, L.-Y. et al. Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer 67, 620-625 (1996).
28. Yu, M. W. et al. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J. Hepatol. 27, 320-330 (1997).
29. Okuda, K. Clinical and public health challenges of cancer. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma vanants. J. Gastroenterol. Hepatol. 17, 401-405 (2002).
30. Johnson, P. J. The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 5, 145-159 (2001).
31. Chen, J.-G. et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J. Med. Screening (in the press).
32. Kim, J. W. & Wang, X. W. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 24, 363-369 (2003).
33. Nawroz, H. et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med. 2, 1035-1037 (1996).
34. Yamada, T. et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin. Cancer Res. 4, 1527-1532 (1998).
35. Esteller, M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
36. Wong, I. H. et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59, 71-73 (1999).
37. Anker, P., Mulcahy, H., Chen, X. Q. & Stroun, M. Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 18, 65-73 (1999).
38. Wong, I. H., Lo, Y. M., Yeo, W., Lau, W. Y. & Johnson, P. J. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. 6, 3516-3521 (2000).
39. Zhong, S. et al. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin. Cancer Res. 8, 1087-1092 (2002). Epigenetic silencing of a gene encoding a carcinogen-detoxification enzyme, GSTP1, is associated with the pathogenesis of HCC.
40. Hsia, C. C., Yowen, H. & Tabor, E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 348, 625-626 (1996).
41. Ming, L. et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36, 1214-1220 (2002). A comprehensive assessment of the separate and combined effects of HBV, hepatitis C virus (HCV) and aflatoxin in causing HCC in Qidong, China.
42. Kuang, S.-Y. et al. Detection of specific mutations in the hepatitis B virus X-gene associated with codon 249 mutations in p53 in hepatocellular carcinoma patients. Proc. Am. Assoc. Cancer Res. 44, 593 (2003).
43. Wang, X. W. et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-182, 43-47 (2002).
44. Wild, C. P. & Turner, P. C. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 17, 471-481 (2002).
45. Staib, F. et al. TP53 and liver carcinogenesis. Hum. Mutat. 21, 201-216 (2003).
46. Kirk, G. D. et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J. Natl Cancer Inst. 92, 148-153 (2000). The first demonstration that mutations of TP53 can be detected in plasma samples of patients with HCC.
47. Jackson, P. E. et al. Specific p53 mutation detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 61, 33-35 (2001).
48. Jackson, P. E. et al. Prospective detection of codon 249 mutations in p53 in plasma of hepatocellular carcinoma patients. Carcinogenesis (in the press).
49. Wild, C. P. & Turner, P. C. in Biomarkers in Cancer Chemopruevention (eds Miller, A. B. et al.) 154, 215-222 (International Agency for Research on Cancer by Oxford University Press, UK, 2001).
50. Sun, T.-T. et al. A pilot study on universal immunization of newborn infants in an area of hepatitis B virus and primary hepatocellular carcinoma prevalence with a low dose of hepatitis B vaccine. J. Cell. Physiol. 4, 83-90 (1986).
51. Chang, M.-H. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336, 1855-1859 (1997). The initial report describing the efficacy of HBV vaccination in reducing the incidence of HCC.
52. Lee, C.-L., Hsieh, K.-S. & Ko, Y.-C. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol. Biomarkers Prev. 12, 57-59 (2003).
53. Busby, W. F. Jr & Wogan, G. N. in Chemical Carcinogenesis 2nd edn, Vol. 2 (ed. Searle, C. E.) 945-1136 (ACS, Washington DC, 1984).
54. Turner, P. C. et al. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea-Conakry, West Africa. J. Gastroenterol. Hepatol. 17, S441-S448 (2002). This study describes the development and use of biomarkers to assess the impact of reduction of aflatoxin exposure on the development of HCC in high-risk populations.
55. Sporn, M. B. & Suh, N. Chemoprevention: an essential approach to controlling cancer. Nature Rev. Cancer 2, 537-543 (2002).
56. Gupta, R. A. & DuBois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev. Cancer 1, 11-21 (2001).
57. 1. A review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res. 399, 245-253 (1998).
58. Kephart, J. C. Chlorophyll derivatives - their chemistry, commercial preparation and uses. Econ. Bot. 9, 3-38 (1955).
59. Young, R. W. & Bergel, J. S. Use of chlorophyllin in the care of geriatric patients. J. Am. Geriat. Soc. 24, 46-47 (1980).
60. 1. Complex formation with the carcinogen. Chem. Res. Toxicol. 8, 506-514 (1995).
61. Egner, P. A. et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl Acad. Sci. USA 98, 14601-14606 (2001). A pivotal clinical trial showing that an 'interceptor' molecule, chlorophyllin, can be used to reduce the bioavailability of aflatoxin in humans.
62. Bergquist, N. R. Schistosomiasis: from risk assessment to control. Trends Parasitol. 18, 309-314 (2002).
63. 1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl. Cancer Inst. 91, 347-354 (1999). This study showed that oltipraz can modulate the effects of aflatoxin in humans through the induction of carcinogen-detoxification enzymes.
64. Kensler, T. W. et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7, 127-134 (1998).
65. Talalay, P. & Talalay, P. The importance of using scientific principles in the development of medicinal agents from plants. Acad. Med. 76, 238-247 (2001).
66. Fahey, J. W., Zalcmann, A. T. & Talalay, P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 56, 5-51 (2001).
67. Zhang, Y., Talalay, P., Cho, C. G. & Posner, G. H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl Acad. Sci. USA 89, 2399-2403 (1992).
68. Fahey, J. W., Zhang, Y. & Talalay, P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl Acad. Sci. USA 94, 10367-10372 (1997). The initial demonstration that high levels of the anticarcinogen isothiocyanate sulphoraphane can be found in 3-day-old broccoli sprouts.
69. Shapiro, T. et al. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol. Biomarkers Prev. 10, 501-508 (2001).
70. Bogaards, J. J., Verhagen, H., Willems, M. I., van Poppel, G. & van Bladdern, P. J. Consumption of Brussels sprouts results in elevated α-class glutathione S-transferase levels in human blood plasma. Carcinogenesis 15, 1073-1075 (1994).
71. Lampe, J. W. et al. Modulation of human glutathione S-transferases by botanically defined vegetable diets. Cancer Epidemiol. Biomarkers Prev. 9, 787-793 (2000).
72. Primiano, T. et al. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res. 55, 4319-4324 (1995).
73. Nakachi, K., Matsuyama, S., Miyake, S., Suganuma, M. & Imai, K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. BioFactors 13, 49-54 (2000).
74. Fujiki, H., Suganuma, M., Imai, K. & Nakachi, K. Green tea: cancer preventive beverage and/or drug. Cancer Lett. 188, 9-13 (2002).
75. Wang, J.-S. et al. Chemoprevention trial of green tea polyphenols in high-risk population of liver cancer. Proc. Am. Assoc. Cancer Res. 44, 1101 (2003).
76. Klaunig, J. E. et al. The effect of tea consumption on oxidative stress in smokers and nonsmokers. Proc. Soc. Exp. Biol. Med. 220, 249-254 (1999).
77. Kang, K. W. et al. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J. 16, 1988-1990 (2002).
78. Muto, Y. et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma: hepatoma prevention study group. N. Engl. J. Med. 334, 1561-1567 (1996). This study describes a clinical chemoprevention trial of polyprenoic acid in a Japanese cohort. HCV infection was the main cause of HCC in more than 70% of patients in the study population. Minimal side effects were reported for 600 mg of polyprenoic acid per day - a treatment that significantly prevented second primary tumours.
79. Okuno, M., Kojima, S. & Moriwaki, H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J. Gastroenterol. Hepatol. 16, 1329-1335 (2001).
80. Lippman, S. M. & Hong, W. K. Cancer prevention by delay. Clin. Cancer Res. 8, 305-313 (2002).
81. Kensler, T. W. et al. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 6, 603-610 (1997).
82. Loeb, L. A., Loeb, K. A. & Anderson, J. P. Multiple mutations and cancer. Proc. Natl Acad. Sci. USA 100, 776-781 (2003).
83. Sun, Z. & Zhu, Y.-R. Multifactorial etiology and multifaceted prevention strategy of hepatocellular carcinoma. Cancer Detect. Prev. 14, 285-289 (1989).
84. Kensler, T. W., Groopman, J. D., Sutter, T. R., Curphey, T. J. & Roebuck, B. D. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol. 12, 113-126 (1999).
85. Kwak, M.-K. et al. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278, 8135-8145 (2003).
86. Itoh, K. et al. A Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys Res. Commun. 236, 313-322 (1997).
87. Itoh, K. et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the aminoterminal Neh2 domain. Genes Dev. 13, 76-86 (1999).
88. Dinkova-Kostova, A. T. et al. Direct evidence that sulfnydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl Acad. Sci. USA 99, 11908-11913 (2002).
89. Ramos-Gomez, M., Dolan, P. M., Itoh, K., Yamamoto, M. & Kensler, T. W. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 24, 461-467 (2003).
90. Ramos-Gomez, M. et al. Sensitivity to carcinogenesis is increased and chemoprotectrve efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl Acad. Sci. USA 98, 3410-3415 (2001).
91. Fahey, J. W. et al. Sulforaphane inhibits extracellular, intracellular, and antiobiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. USA 99, 7610-7615 (2002).